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Abstract 
New antibiotics are urgently needed to address multidrug resistant (MDR) bacteria. Herein we 
report that second generation (G2) peptide dendrimers bearing a fatty acid chain at the dendrimer 
core efficiently kill Gram-negative bacteria including Pseudomonas aeruginosa and Acinetobacter 
baumannii, two of the most problematic MDR bacteria worldwide. Our most active dendrimer 
TNS18 is also active against Gram-positive methicillin resistant Staphylococcus aureus (MRSA). 
Based on circular dichroism and molecular dynamics studies we hypothesize that TNS18 adopts a 
hydrophobically collapsed conformation in water with the fatty acid chain backfolded onto the 
peptide dendrimer branches, and that the dendrimer unfolds in contact with the membrane to expose 
its lipid chain and hydrophobic residues, thereby facilitating membrane disruption leading to rapid 
bacterial cell death. Dendrimer TNS18 shows promising in vivo activity against MDR clinical 
isolates of A. baumannii and E. coli, suggesting that lipidated peptide dendrimers might become a 
new class of antibacterial agents.  
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Introduction 
Multidrug resistant (MDR) Pseudomonas aeruginosa and Acinetobacter baumannii have been 
listed, together with Enterobacteriaceae, as the most critical human pathogens in a February 2017 
call for new antibiotics by the World Health Organization. Most approaches currently available to 
address this call rely on screening natural product sources such as soil bacteria or small molecule 
drug libraries, which comprise molecules either made by nature or closely related to known drugs 
and natural products.
1-3
  
 One important alternative consists in designing analogs of antimicrobial peptides (AMPs), a 
broad class of naturally occurring cyclic or linear peptides which mostly kill bacteria by a 
membrane disruptive mechanism.
4-8
 These designed analogs are expected to overcome the typical 
limitations of peptides in terms of stability. Most reports to date exploited classical linear or cyclic 
chain topologies while introducing alternative building blocks such as D-enantiomeric
9-12
 and β-
amino acids,
13
 peptoids,
14-20
 nylon,
21, 22
 or urea linked diamines.
23, 24
 In our approach by contrast, we 
explore unusual multibranched topologies of the peptide chain, such as peptide dendrimers and 
bicyclic peptides, while keeping building blocks constant.
25-27
 Extending on previous reports that 
multivalent display of AMPs on a poly-lysine tree can increase their antimicrobial activity,
28-30
 we 
recently identified the third generation (G3) antimicrobial peptide dendrimer (AMPD) G3KL 
consisting of a lysine-leucine dipeptide repeated across the dendrimer branches active against P. 
aeruginosa and A. baumannii laboratory strains,
31
 as well as against a broad panel of multidrug 
resistant clinical isolates of both of these pathogens,
32
 and with favorable pro-angiogenic properties 
in biological burn-wound bandages.
33
  
 We had initially obtained G3KL by exploiting a dendritic effect on antimicrobial activity, 
i.e. an increase in antibacterial activity with dendrimer generation, with the consequence that G3KL 
was relatively large and difficult to synthesize in high yields. Here we set out to search for a smaller 
but equally active version of this AMPD by focusing on the second generation (G2) peptide 
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dendrimer G2KL, which only showed activity against P. aeruginosa in LB (Luria-Bertani) 
medium, but not in MH (Müller-Hinton) medium which is more relevant to antibiotic use, probably 
due to the higher magnesium ion concentration. To increase the activity of G2KL, we investigated 
the effect of adding a short fatty acid chain to the dendrimer because such fatty acid chains are 
found in many AMPs where they play an essential role for their activity,
34, 35
 including the case of 
polymyxin B, a last resort cyclic peptide antibiotic against Gram-negative MDR bacteria used here 
as a positive control, but against which resistance is appearing.
36-39
 Furthermore lipidation is often 
used to extend the circulation time of peptides in vivo by inducing binding to serum albumin,
40
 
which extends their circulation time as demonstrated for insulin
41
 as well as for GLP-1 analogues.
42
  
Here we report how the addition of a fatty acid to the core of G2KL followed by a 
combinatorial sequence optimization led us to discover AMPD TNS18, which is only half the size 
of G3KL yet displays a broader antibacterial activity spectrum including not only Gram negative 
MDR strains of P. aeruginosa and A. baumannii, but also methicillin resistant Staphylococcus 
aureus (MRSA). By profiling with P. aeruginosa LPS deletion mutants we show that the added 
lipid chain is essential to confer activity. TNS18 apparently acts by a membrane disruptive 
mechanism, evidenced by the very fast killing kinetics, the formation of disrupted cellular structures 
visible by transmission electron microscopy (TEM), and vesicle leakage experiments. Circular 
dichroism (CD) and molecular dynamics (MD) studies suggest that the dendrimer exists in a 
hydrophobic collapsed conformation in water with its fatty acid chain backfolded onto a 
hydrophobic pocket formed by the peptide dendrimer branches. We suggest that the dendrimer 
unfolds in contact with the membrane enabling membrane disruption and rapid bacterial killing. 
TNS18 is stable in serum and shows promising activity in a murine infection model with MDR 
clinical isolates of A. baumannii and E. coli, providing the first evidence that AMPDs might be 
amenable to in vivo use.  
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Figure 1. Structure and sequence of G2 AMPD TNS18. Residues are colored by dendrimer generation: G0 = red (one 
copy), G1 = blue (2 copies), G2 = black (4 copies).   
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Results and Discussion 
Lipidation confers antibacterial activity to G2 AMPDs 
To obtain lipidated versions of our G2 peptide dendrimer G2KL we attached an additional lysine 
residue at the dendrimer core and acylated its side chain amino group with fatty acids of increasing 
length. We prepared these dendrimers by solid-phase peptide synthesis (SPPS),
43
 which is suitable 
to prepare a variety of peptide dendrimers,
25
 starting with a side chain alloc protected lysine.
44
 After 
completing the G2 branch by coupling of the last four lysine residues, we selectively deprotected 
the alloc group at the dendrimer core, acylated the resulting free amino group with fatty acids of 
various chain length (C6 to C24), and finally removed the four Fmoc groups at the dendrimer 
periphery and cleaved the dendrimer from the resin and deprotected the remaining Boc-protected 
lysine side chains by acidic treatment. The procedure provided lipidated dendrimers in pure form 
and good isolated yields after purification by preparative HPLC (Scheme 1, Table 1).  
 We tested our lipidated peptide dendrimers for antimicrobial activity against P. aeruginosa 
PAO1 and Escherichia coli DH5α as Gram negative and Bacillus subtilis BR151 as Gram positive 
bacterium, as well as for their hemolytic activity on human red blood cells (Table 1). The addition 
of the side-chain acylated lysine yielded active AMPDs with all acyl chain length tested (C6 to C24). 
Elongation of the fatty acid however also led to a gradual increase in hemolysis to the point that 
hemolysis was even stronger than the antimicrobial effect for C18 and C24. From these experiments, 
we selected the decanoyl group (C10, TNS03) as the optimal aliphatic chain length combining good 
antimicrobial effects on all three test strains with moderate hemolysis. 
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Scheme 1. Synthesis and structure of lipidated peptide dendrimer TNS03. Residues are colored by peptide chain: black 
= main α-peptide chain; blue = peptide chain branched off the G0 side-chain branching; red = peptide chain branched 
off the G1 side-chain branching. Conditions: a) SPPS; b) Pd(Ph3)4, PhSiH3, in dry DCM, then decanoic acid, HOBt, 
DIC, DIPEA; c) 20% piperidine in DMF, then TFA cleavage and HPLC purification. 
 
Table 1. Synthesis and biological activity of AMPDs.  
Compound Sequencea) 
Yieldb) 
mg (%) 
MS 
calc./obs. 
P. 
aeruginosac) 
MIC (µg/mL) 
E. colic) 
MIC 
(µg/mL) 
B. sub.c) 
MIC 
(µg/mL) 
hRBCc) 
MHC 
(µg/mL
) 
G3KL (KL)8(KKL)4(KKL)2KKL 124 (23) 4531.38/4533.38 4 4 3 840 
G2KL (KL)4(KKL)2KKL 86 (34) 2089.56/2090.57 >64
d > 85 > 85 > 1700 
TNS01 (KL)4(KKL)2KKLK(C6) 23.0 (13) 2315.73/2315.74 16 2 20 1540 
TNS02 (KL)4(KKL)2KKLK(C8) 27.4 (13) 2343.76/2343.77 4 1 4 1190 
TNS03 (KL)4(KKL)2KKLK(C10) 84 (30) 2371.80/2371.80 3 1 2 650 
TNS04 (KL)4(KKL)2KKLK(C12) 39.8 (18) 2399.83/2399.83 3 1 2 165 
TNS05 (KL)4(KKL)2KKLK(C16) 30.2 (14) 2455.89/2455.90 8 12 nd 11 
TNS06 (KL)4(KKL)2KKLK(C18) 52.6 (16) 2483.92/2483.92 9 3 4 2 
TNS07 (KL)4(KKL)2KKLK(C24) 56.7 (17) 2568.01/2568.01 54 13 26 1 
a) One letter code for amino acids. Branching diamino acids in italics. All peptides are carboxamides (CONH2) at the C-terminus. Cn 
denotes a Cn-fatty acid amidated to the side-chain amino group of Lys in the core. 
b) Yields given for RP-HPLC purified product. c) 
MIC (minimal inhibitory concentration were determined on P. aeruginosa PAO1 in Müller-Hinton medium, Escherichia coli DH5α 
in LB medium, and Bacillus substilis BR-151 in LB medium, and MHC (minimal hemolytic concentration) determined on human red 
blood cells (hRBC). Experiments were done in triplicates, values are given in µg/mL and are calculated based on the peptide mass 
without trifluoroacetate counter ions. nd = not determined. d) a MIC value of 7 µg/mL was obtained in LB medium.31  
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Sequence optimization leads to more potent G2 AMPDs 
We next optimized the amino acid sequence of G2KL focusing on conservative amino acid 
exchanges in the G1 and G2 branches keeping the alternating hydrophobic and cationic residues 
motif. We prepared a 1936-member peptide dendrimer library
45
 using split-and-mix synthesis with 
a tentagel resin bearing an acid stable but photolabile linker (Figure 2a).
46, 47
 Lysines at X
5
 and X
8
 
were exchanged to ornithine (Orn), diaminobutyric acid (Dab), arginine and histidine, but not lysine 
to avoid confusion with the branching lysines during the bead decoding step.
45
 Leucines X
4
 and X
7
 
were exchanged to phenylalanine, valine, methionine, proline, and leucine itself, as well as to β-
alanine (β-Ala), γ-amino butyric acid (GABA) and 4-aminomethyl-benzoic acid (AMBA) to test the 
effect of dendrimer branch extension on activity. The polar residues threonine, asparagine and 
glutamate were also included to test if activity might be compatible with these less hydrophobic 
residues which are also found in naturally occurring AMPs. The library featured a free carboxyl 
group at the C-terminus liberated by photolysis, which was expected to reduce the antimicrobial 
effect and facilitate the selection of the most active sequences since the high concentration of 
peptide around the photolyzed bead might produce an exceedingly high fraction of active beads. 
 Antimicrobial activity screening was performed by partial photolysis of dried synthesis 
beads,
46
 spreading the beads on an agar plate inoculated with PAO1, incubation at 37°C  overnight, 
staining of live bacteria, and identification of beads surrounded by a clearing zone indicative of 
antimicrobial activity (Figure 2b).
48
 We screened five agar plates, each with 10 mg of library 
(approx. 10,000 beads), and identified a total of 64 beads with clearing zones (11 beads with large, 
28 with medium, 25 with small clearing zones, Table S1), which we picked and subjected to amino 
acid analysis for sequence determination.
49
 Compared to randomly picked beads showing an 
approximately statistical sequence distribution (Table S2), the most active sequences carried 
preferentially phenylalanine and leucine at both hydrophobic residue positions X
4 
and X
7
, 
diaminobutyric acid at the cationic residue position X
5
 within the G1 branch, and ornithine or 
arginine at the terminal cationic residue position X
8
 (Figure 2c). The preference for these residues 
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was quite strong, with three sequences occurring several times among active beads (15, 14 resp. 7 
times). By contrast extended (e.g. β-Ala) or polar (e.g. Thr) residues were not present among the 
hits, suggesting limited sequence diversity options within this G2 peptide dendrimer architecture.  
 We resynthesized and tested the three most frequently found sequences together with 
another five single occurrence hits and two non-hit sequences from beads without any detectable 
clearing zone (Table 2). While the two non-hit sequences as well as the starting sequence G2KL 
were inactive when tested in MH medium, six of the eight resynthesized G2 dendrimer hits showed 
activity against PAO1 under these conditions. We selected the three most frequently found hit 
sequences TNS08, TNS09 and TNS10 and prepared the corresponding lipidated dendrimers 
TNS18, TNS19 and TNS20 as possible improved versions of TNS03. Indeed, all three AMPDs 
displayed excellent activity against PAO1. Although lipidation might enhance protein binding, the 
antimicrobial activity of our lipidated dendrimers was only slightly reduced in the presence of 
human serum. We also measured the stability of the various dendrimers towards degradation in 
human serum (Figure S1). We observed that while G2KL (t1/2 = 14 h) became slightly more prone 
to degradation upon lipidation to TNS03 (t1/2 = 8 h), the relatively unstable dendrimer TNS08 (t1/2 = 
6 h) was more stable in its lipidated form TNS18 (t1/2 = 20 h), which was as stable as the G3 AMPD 
G3KL (t1/2 = 18 h). As observed with TNS03 the presence of a lipid chain in TNS18, TNS19 and 
TNS20 also led to a stronger hemolysis effect compared to the parent non-lipidated dendrimers 
TNS08, TNS09 and TNS10, however the effect was judged acceptable considering the gain in 
activity obtained by lipidation.  
 We further profiled our lipidated AMPDs against a broader panel of bacteria comprising 
four MDR clinical isolates of P. aeruginosa, A. baumannii 19606, three strains of E. coli, and 
Stenotrophomonas maltophilia CP127, all of which belong to problematic Gram-negative 
pathogens. We also tested Staphylococcus epidermidis, S. aureus COL (methicillin resistant) and S. 
aureus Newman (methicillin sensitive) as Gram positive bacteria (Table 3). Remarkably, our 
sequence optimized lipidated G2 AMPDs were not only more active than the previous best and 
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much larger AMPD G3KL or the starting sequence TNS03, but for the first time they were now 
also active against Gram positive bacteria including MRSA, against which polymyxin or G3KL or 
TNS03 were inactive. TNS18 with ornithine (X
8
), phenylalanine (X
7
), diaminobutyric acid (X
5
) and 
leucine (X
4
) stood out as the most active AMPD in the series.  
 
Figure 2. Optimization of the G2KL peptide dendrimer sequence. (a) Structure and sequence composition of the 1936-
member combinatorial peptide dendrimer library. (b) PAO1 antimicrobial activity screening on agar plates inoculated 
with PAO1. After addition of dried photolyzed bead the plates were incubated at 37°C overnight and stained for live 
bacteria with MTT. Beads surrounded by a clearing zone indicative of antimicrobial activity are highlighted. (c) Amino 
acid composition of dendrimers in beads with large, medium or small clearing zone, and of control beads picked 
randomly before photolysis. Sequences of all beads analyzed are given in Table S1 and S2.   
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Table 2. Synthesis and activity of reference compounds, library hits, non-hits, and selected lipidated hits. 
Compound Sequencea) 
No. of 
hitsb) 
Yield 
mg (%)c) 
MS calc./obs.d) 
       PAO1 
MICe) (µg/mL)          
MH    + serum 
serum 
t1/2
f) 
hRBC 
MHCg) 
(µg/mL) 
Polymyxin B Cyclic peptide - - - 2-4   >2000 
G3KL (KL)8(KKL)4(KKL)2KKL - 124 (23) 4531.38/4533.38 4 4 18 h 1000 
G2KL (KL)4(KKL)2KKL - 86 (34) 2089.56/2090.57 >128 >128 14 h >2000 
TNS03 (KL)4(KKL)2KKLK(C10) - 84 (30) 2371.80/2372.79 4 8 8 h 1000 
Library Hits:         
TNS08 (OF)4(KBL)2KKL 15 44 (17) 2113.38/2113.38 32 32 6 h >2000 
TNS09 (OL)4(KBF)2KKL  14 30 (22) 2045.41/2045.41 >128 >128  >2000 
TNS10 (RF)4(KBL)2KKL 7 44 (13) 2281.46/2281.47 16 32  >2000 
TNS11 (OF)4(KBβA)2KKL 1 38 (16) 2029.28/2029.28 >128   >2000 
TNS12 (BL)4(KBL)2KKL 1 28 (12) 1921.37/1921.37 128   1000 
TNS13 (RX)4(KBF)2KKL 1 28 (15) 2293.37/2293.37 64    
TNS14 (RE)4(KBL)2KKL 1 32 (14) 2209.36 /2209.36 >128   1000 
TNS15 (RL)4(KHF)2KKL 1 42 (12) 2287.49/2287.49 128   >2000 
Non-hits:         
TNS16 (BT)4(KRL)2KKL - 36 (11) 1985.30/1985.31 >128    
TNS17 (OZ)4(KHV)2KKL - 12 (5) 1911.27/1911.28 >128   >2000 
Lipidated hits:         
TNS18 (OF)4(KBL)2KKLK(C10) - 121 (42) 2395.61/2395.61 2 8 20 h 500 
TNS19 (OL)4(KBF)2KKLK(C10) - 28 (9) 2327.64/2327.64 2 8 24 h 500 
TNS20 (RF)4(KBL)2KKLK(C10) - 24 (11) 2563.69/2563.70 4-8 16 18 h 500 
a) One-letter codes for amino acids, O = ornithine, X = 4-aminomethyl-benzoic acid, Z = γ-aminobutyric acid, B = diaminobutyric 
acid, K = branching lysine, βA = β-alanine, K(C10) = side-chain decanoylated lysine. C-termini are carboxamide CONH2. 
b) number 
of times the sequence was found on beads marked as active in agar plate screening. c) Yields given for RP-HPLC purified product. d) 
High resolution electrospray ionization mass spectrometry (positive mode), the calculated monoisotopic mass and the observed mass 
in the reconstructed spectrum are given. e) MIC (minimal inhibitory concentration) were determined on P. aeruginosa PAO1 in 
Müller-Hinton medium, with or without 30% v/v human serum. f) half-life for degradation in human serum as determined by 
analytical HPLC, see methods for details. g) MHC (minimal hemolytic concentration) determined on human red blood cells (hRBC). 
Experiments were done in triplicates, values are given in µg/mL and are calculated based on the peptide mass without trifluoroacetate 
counter ions. Missing entries were not determined. 
 
 
Table 3. Activity of AMPDs against multidrug resistant clinical isolates of P. aeruginosa and other bacteria strains.
a)
  
 Polymxin B G3KL TNS03 TNS18 TNS19 TNS20 
MDR P. aeruginosa       
ZEM-9A 8 32-64 16-8 8 8 16-32 
ZEM-1A <1 4 4 4 4 4-8 
PEJ9.1 2 64 64 32 >64 32 
PEJ2.6 1 16 8 4 16 8 
Gram negative bacteria       
A.baumannii 19606 <1 8-16 16 8-16 32 8-16 
E. coli (CP46) <0.5 >64 32 8 n.d. 8-4 
E. coli W3110 (TE823) <0.5 8 4 4 n.d. 4 
E. coli MG1665 (TE824) <0.5 8 4 4 n.d. 4 
St. maltophilia (CP127)   >64 64 64 16 n.d. 16 
Gram positive bacteria       
S.epidermidis 64 2 2 2 2 2 
S.aureus COL 64 >64 64 8-16 32-64 8 
S.aureus Newman >64 >64 64 16 n.d. 8 
a)
 Minimal inhibitory concentrations (MIC) given in µg/mL were determined in Müller-Hinton medium. Experiments 
were done in triplicates. Values are calculated based on the peptide mass without trifluoroacetate counter ions. n.d. = 
not determined.  
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G2 dendrimers require the core lipid chain to pass the LPS layer  
To better understand the role of the lipid chain in the activity of TNS18 and analogs we profiled our 
G2 dendrimers against wild-type PAO1, a PAO1rmd mutant (PT1482) lacking the A-band 
lipopolysaccharide (LPS) composed of D-rhamnose trisaccharides, and a PAO1rmlC mutant 
(PT1495) lacking both A- and B-band of the LPS.
50
 The non-lipidated G2 dendrimers such as 
TNS08 were all inactive against PAO1 and PAO1rmd (PT1482), but showed good activity against 
PAO1rmlC (PT1495) lacking both A- and B-band LPS components (Table 4). By contrast, TNS18 
and related lipidated G2 dendrimers were active on all variants independent of the LPS composition 
of the bacterial outer membrane, similarly to polymyxin B and our previous G3 dendrimer G3KL. 
This data indicated that the core fatty acid on G2 dendrimers is required for passing the LPS layer, 
which is similar to the reported effect of the N-terminal fatty acid appendage of polymyxin B.
36
  
 
Table 4. Antimicrobial activity of AMPDs against PAO1 and LPS deletion mutants of P. aeruginosa.  
AMPD 
PAO1 
 
PAO1rmd 
(A-) 
PAO1rmlC 
(A-B-) 
Polymyxin B 1 1 <1 
G2KL >64 >64 16 
G3KL 4 4 4 
TNS02 10 10 5 
TNS03 8 4 4 
TNS04 5 5 4 
TNS08 >64 >64 4 
TNS09 >64 >64 8 
TNS10 >64 64 4 
TNS18 4 4 2-4 
TNS19 4-8 4 4 
TNS20 8 8 4 
MIC (µg/mL) was determined in MH-medium on a 96 well plate and incubation overnight (18-22 hours) at 37°C. 
Maximal measured concentration is 64 µg/mL. Each AMPD was measured in two independent duplicates. 
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Lipidated AMPDs disrupt bacterial membranes 
Time-kill experiments showed complete killing of PAO1 within 30 min of incubation with TNS18, 
which was slightly faster than for TNS03 (1h), polymyxin B and G3KL (2h), or tobramycin (3h) 
(Figure 3). Rapid killing is often indicative of a membrane disruptive mechanism of action.
51
 
Analysis by transmission electron microscopy (TEM) showed that treating PAO1 cells with 
polymyxin B (10×MIC, 5 µg/mL) for 15-60 min produced characteristic protrusions in the outer 
membrane of PAO1, reproducing earlier reports,
52
 while control cells were unaffected. Under the 
same conditions AMPDs TNS03 and TNS18 (10×MIC, 40 µg/mL) produced even more significant 
membrane perturbations leading to emptying of the cell content (Figure 4a, Figure S2). Similar 
effects were observed with the larger AMPD G3KL, suggesting a similar mechanism for G2 and 
G3 dendrimers. On the other hand, the non-lipidated dendrimer G2KL only produced a very weak 
effect, and this only at a much higher concentration (128 µg/mL), in line with its very weak activity.   
The membrane disruptive activity of our lipidated G2 dendrimers was further evidenced by 
vesicle leakage experiments with large unilamellar vesicles (LUVs). Treating fluorescein loaded 
LUVs consisting of the anionic lipid phosphatidyl glycerol mimicking the bacterial membrane with 
Polymyxin B led to fluorescein release as evidence for membrane perturbation (Figure 4b). 
Dendrimers TNS03, TNS18 and G3KL produced a similar effect, but with somewhat faster 
kinetics of release, while G2KL lacking the lipid chain was less and slower acting. By contrast 
LUVs consisting of the zwitterionic lipid phosphatidyl ethanolamine mimicking the eukaryotic 
membrane were only weakly affected by these compounds, in line with their relatively modest 
hemolytic activity (Figure 4c). 
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Figure 3. Time-kill assay showed P. aeruginosa bacteria cell death at 37°C in MH medium measured at 2×MIC for 
Tobramycin (0.5 µg/mL), Polymyxin B (0.5 µg/mL), G3KL (8 µg/mL), TNS03 (8 µg/mL), and TNS18 (8 µg/mL).  
 
 
Figure 4. Membrane disruptive properties of AMPDs. (a) TEM images of P. aeruginosa cells treated for 60 min. at 
10×MIC with Polymyxin B (5 µg/mL), TNS18 (40 µg/mL), TNS03 (40 µg/mL), and G3KL (40 µg/mL) and G2KL 
(128 µg/mL). Enlarged TEM images are shown in Figure S2. (b) Fluorescein leakage assay from phosphatidyl glycerol 
LUVs. (c) Fluorescein leakage assay from phosphatidyl choline LUVs. LUVs were suspended in buffer (10 mM TRIS, 
107 mM NaCl, pH 7.4). After 50 sec the indicated compound was added to reach the indicated concentration. After 300 
sec 1.2% Triton X-100 was added for full fluorescein release.    
 
0
2
4
6
8
10
0 1 2 3 4 5 6 7
lo
g
 c
fu
/m
L
Time (h)
Blank
Tobramycin
Polymyxin B
G3KL
TNS03
TNS18
Page 14 of 26
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15 
 
Spectroscopic studies   
Diffusion NMR showed hydrodynamic radii expected for a monomeric state in aqueous buffer at 
different pH and in the presence of trifluoroethanol (TFE) (Figure S3, Table S3). Furthermore we 
did not detect any micelle formation up to 10 mg/mL using the Nile Red assay,
53
 excluding micelle 
formation as a possible explanation for antimicrobial activity (Figure S4).  
 Many linear AMPs undergo a conformational transition in contact with the bacterial 
membrane leading to the formation of a membrane disruptive amphiphilic structure,
4-8
 which is 
most often an α-helix observable by circular dichroism (CD) in aqueous buffer upon addition of 
20% v/v TFE.
54
 Here we found that TNS03 (Figure 5a), and to a lower extent G2KL (Figure 5b), 
behaved similarity to linear α-helical AMPs by showing a typical random coil signal in neutral 
aqueous buffer with transition to an α-helical signal upon addition of 20% v/v TFE, a situation 
observed previously with AMPD G3KL which has a similar sequence.
31
 TNS18 behaved similarly, 
although its CD signals in water and in the presence of TFE did not resemble the CD signature of 
linear random coils and α-helices as perfectly as those of TNS03 (Figure 5c). Its non-lipidated 
analog TNS08 showed a similar but also rather weak CD signal transition upon addition of TFE 
(Figure 5d).  
 Taken together, these spectroscopic studies showed that TNS18 and related G2 AMPDs 
were not aggregating in water, but underwent a conformational transition to an α-helix like 
conformation when exposed to TFE similarly to typical AMPs.  
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Figure 5. CD spectra of AMPDs (200 µg/mL) in 8 mM aqueous phosphate buffer pH 7.4 (PB) with increasing 
percentage of trifluoroethanol (TFE). (a) TNS03. (b) G2KL. (c) TNS18. (d) TNS08. 
 
Molecular modelling 
The α-helical CD signals observed with our dendrimers in the presence of TFE might be explained 
by folding of the linear α-nonapeptide present along the α-peptide backbone of the dendrimer 
(Scheme 1) into a standard α-helix as observed previously with G2 peptide dendrimers designed to 
include an α-helix in their structure.
55
 To test this hypothesis, we built the corresponding structural 
models for our most active AMPD TNS18 and its analog TNS03, and performed molecular 
dynamics (MD) simulations over 500 ns at 300 K in water with or without 20% TFE using the 
GROMACS molecular modeling package.
56
  
 Both dendrimers rapidly unfolded in pure water, but their α-helical structures were partly 
stabilized in the presence of 20% TFE, in line with the CD data (Figure 6a and Figure S5a). The 
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helix stabilization effect with 20% TFE was most pronounced with TNS18, whose central α-peptide 
chain retained its α-helical conformation over the course of the entire simulation. A snapshot of the 
dendrimer after 100 ns showed an extended fatty acid and hydrophobic residues exposed to the 
solvent, which might correspond to the conformation of the dendrimer within the membrane 
environment (Figure 6b/e). In the case of TNS03 the initial α-helical folding of the central α-peptide 
chain was only partially preserved during the first 200 ns of the simulation. In this case the snapshot 
at 100 ns showed a hydrophobically collapsed state with a backfolded fatty acid chain and cationic 
residues exposed to the solvent, as expected for a conformation in water (Figure S5b/c). 
 To test if a hydrophobically collapsed structure might also exist for TNS18 in water, we 
equilibrated its structure by MD at 450 K, and performed 10 parallel cooling cycles from 10 
different starting high energy conformations sampled at 450 K. Seven out of ten trajectories 
converged to a consistently compact conformation at 300 K. This structure showed a β-sheet like 
pattern involving up to five backbone H-bonds connecting the main α-peptide branch spanning from 
G0 through G2 with one each of the G1 and G2 dipeptides (Figure 6c).  This β-sheet like 
conformation, which might explain the somewhat unusual CD signal of TNS18, was also reflected 
in the Ramachandran plot, where 73 % of the (φ, ϕ)-angles resided in the β-sheet region (Figure 
6d). In this conformation the lipid chain at the dendrimer core is backfolded onto the peptide 
dendrimer branches forming a hydrophobic pocket, resulting in hydrophobically collapsed globular 
structure exposing cationic residues on the outside (Figure 6f). This structure can be interpreted as 
the non-aggregating conformation of the dendrimer in water.  
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Figure 6. Molecular dynamics simulation of AMPD TNS18. (a) MD trajectory of TNS18 as RMSD plot of the central 
helix from the starting fully α-helical conformation in water (red line) and with 20% TFE in water (black line). (b) stick 
model of the backbone of TNS18 after 100 ns in an α-helical conformation. (c) Stick model of the minimized, 
hydrophobically collapsed β-sheet like structure of TNS18 in water after simulated annealing and clustering. (d) 
Ramachandran plot of peptide bond angles in the structures of TNS18 at 300 K from 7 independent simulated annealing 
MD runs. (e) CPK model of the structure shown in (b). (f) CPK model of the structure shown in (c). 
 
Mechanistic hypothesis 
The experiments and modeling studies above suggest a possible mechanism of action in which 
dendrimer TNS18 exists in a hydrophobically collapsed β-sheet like conformation in water (Figure 
5c and Figure 6c/f) explaining the observed good water solubility and absence of aggregation. This 
folded conformation should persist when the dendrimer traverses the relatively polar LPS layer, and 
unfold in contact with the membrane to an extended and possibly α-helical conformation (Figure 
6b/e) exposing its lipid chain and hydrophobic side chains and enabling interaction with membrane 
lipids, leading to accumulation and eventually membrane perturbation and bacterial killing (Figures 
3 and 4).  
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 The MD simulations suggest that the stronger antibacterial activity of the sequence 
optimized TNS18 compared to its parent dendrimer TNS03 might reflect stronger stabilization of 
the extended and membrane disruptive conformation compared to the hydrophobically collapsed 
state. The data with LPS mutant strains (Table 4) suggest that the non-lipidated dendrimers TNS08 
and G2KL remain in the LPS layer and cannot accumulate in the membrane by lack of a lipid 
appendage, explaining their lower activity. In the case of G3KL, its larger size and number of 
positive charges (23+) compared to G2 dendrimers (9+) probably allows binding interactions with 
the negatively charged lipid A and membrane accumulation even without a lipid chain. It should be 
noted that our dendrimers do not seem to form amphiphilic conformations segregating cationic and 
hydrophobic residues in two groups as often observed with linear α-helical AMPs, suggesting that 
membrane perturbation might occur via the “carpet” model rather than by pore formation.
5
 
In vivo activity 
To test if our dendrimers might be used in vivo we carried out a preliminary study in a mouse 
infection model. We considered our best lipidated G2 dendrimer TNS18 as well as our earlier 
G3KL, which had not been previously tested in vivo. Both dendrimers were converted from their 
trifluoroacetate salt to acetate salt by ion exchange for in vivo studies.
57
  In this model, we used an 
MDR A. baumannii strain abaX1605034 (Table S4), which was sensitive in vitro to Polymyxin B 
(MIC = 1-2 µg/mL) as well as to both AMPDs (MIC = 4-8 µg/mL).  
 BALB/c mice were infected intraperitoneally with 1.6×10
8
 CFU bacterial cells, and treated 
with three successive injections (t = 0 h, 8 h, 16 h) of 5 mg/kg AMPD, polymyxin, or saline as a 
control.  While all but one mice died within 15 h when left untreated, mice treated with TNS18 
showed complete survival, which was comparable to the effect with polymyxin B (Figure 7a). On 
the other hand our previously reported G3 dendrimer G3KL was ineffective in this in vivo infection 
model. Non-infected mice treated with the same amounts of G3KL of TNS18 were entirely 
unaffected, showing that the dendrimers were not toxic by themselves. In a second series of 
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experiments we also tested TNS18 to treat mice intraperitoneally infected by a MDR Escherichia 
coli strain and similarly observed 100% survival of treated animals. By comparison imipenem, to 
which the strain is sensitive, only provided partial protection, and ceftriaxone, to which the strain is 
resistant, was even less effective (Figure 7b).    
 
Figure 7. In vivo activity of AMPDs. (a) Survival of mice over time infected by MDR A. baumannii strain 
abaX1605034 (0.5 mL of 3.2×10
8
 CFU/mL) and treated with 3 x 5 mg/kg Polymyxin B or AMPD (0h, 8h, 16h). (b) 
Survival of mice over time infected by MDR E. coli strain SP1708 (0.5 mL of 3.5×10
8
 CFU/mL) and treated with 
TNS18 (3 × 5 mg/kg, MIC = 8 µg/mL), Ceftriaxone (3 x 5 mg/kg, MIC > 64 µg/mL) or imipenem (3 × 0.2 mg/kg, MIC 
< 1 µg/mL).  
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Conclusion 
The experiments above show that lipidated G2 peptide dendrimer TNS18 exerts potent 
antimicrobial effects against MDR Gram negative bacteria such as P. aeruginosa, A. baumannii and 
E. coli, as well as against Gram positive bacteria such as MRSA, for which G3KL, TNS03 or the 
reference antibiotic polymyxin B are inactive. Profiling with P. aeruginosa LPS deletion mutants 
show that the presence of the lipid chain is essential to enable penetration of the lipopolysaccharide 
layer. The very rapid killing kinetics, the induction of membrane punctures and emptying of cell 
contents visible by TEM, and direct interactions with bacterial membrane lipids in vesicle leakage 
experiments with LUVs, indicate that our dendrimer exert potent membrane perturbation effects of 
bacteria. Spectroscopic studies combined with MD simulations suggest that TNS18 adopts a 
hydrophobically collapsed β-sheet like conformation in water with its lipid chain backfolded onto 
the peptide dendrimer. As a possible mechanism of action against Gram-negative bacteria, we 
propose that the dendrimer traverses the LPS layer in this hydrophobically collapsed conformation, 
and then unfolds in contact with the membrane to form an α-helical like conformation exposing its 
hydrophobic side chains and fatty acid, thereby enabling accumulation and membrane perturbation. 
A preliminary in vivo study with a murine infection model using MDR A. baumannii and E. coli 
clinical isolates shows promising activities for TNS18. Taken together, these data suggest that 
lipidated G2 AMPDs might be promising candidates for further development as new antimicrobial 
agents.  
Methods 
Synthesis and characterization of peptide dendrimers and all assays, measurements, and modeling 
studies are described in the supporting information. 
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Supporting information. Details of synthesis and characterization of peptide dendrimers and all 
assays, measurements, and modeling studies. This information is available free of charge at 
http://pubs.acs.org. 
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